Iomeprol

Summary

Iomeprol (CHEMBL2107214) is an approved small-molecule radioopaque medium (ATC V08AB10); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB10
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 777.1 Da · C17H22I3N3O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107214
Name	Iomeprol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3731
ChEBI	CHEBI:31710
ATC	V08AB10
Molecular formula	C17H22I3N3O8
Molecular weight	777.1
InChIKey	NJKDOADNQSYQEV-UHFFFAOYSA-N

SMILES: CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO

IUPAC name: 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-methylamino]-2,4,6-triiodobenzene-1,3-dicarboxamide

ChEBI definition: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.

Pharmacological roles (ChEBI): radioopaque medium.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: E-7337, E7337, Iomeprol, Iomeron 300, Iomervu, IOMEPROL, SID144207160

Patent coverage: 1,025 distinct patent families (3,685 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00390585	PHASE4	COMPLETED	Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)
NCT01255722	PHASE4	COMPLETED	Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
NCT00280410	PHASE2/PHASE3	COMPLETED	Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).